Sep 9, 2020Bayer Collaborates with Recursion to Strengthen Digital Drug Discovery and Advance New Therapies for Fibrotic Diseases- Drug discovery partnership and equity investment led by Leaps by Bayer in Series D financing round
Berlin, Germany and Salt Lake City, USA, September 9, 2020 – Bayer and US-based Recursion Pharmaceuticals, Inc., a digital biology company industrializing drug discovery, have entered into a...
Sep 9, 2020Recursion Secures $239 Million in Equity Financing to Advance Technology-Enabled Drug Discovery Platform and Pipeline− Proceeds to support Recursion’s development of its broad clinical-stage pipeline and expansion of the capabilities of its drug discovery platform −
SALT LAKE CITY, September 9, 2020 — Recursion, a digital biology company industrializing drug discovery, today announced a $239 million oversubscribed Series D financing. The financing was led...
Jul 28, 2020
SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a digital biology™ company leading in the industrialization of drug discovery, today announced its acquisition of Vium, a digital vivarium™ company....
Jun 25, 2020Imaging system from Molecular Devices helps Recursion produce the largest publicly available set of human cellular morphological data for COVID-19 therapeutic researchMore than 305,000 high-resolution, multi-channel COVID-19 cellular images captured in less than four weeks with Molecular Devices ImageXpress® Micro Confocal High-Content Imaging System are now available to the scientific community.
SAN JOSE, Calif. – June 25, 2020 — With the COVID-19 pandemic impacting millions around the globe, researchers are racing to develop a vaccine or drug treatment. In an effort to better...
Nov 8, 2018Recursion Secures $1.6M NIH Phase 2 SBIR Grant to Identify Therapeutic Candidates for Senescence, a Key Age-Related Disease Process
Recursion Pharmaceuticals, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, today announced a $1.6...